Le Lézard
Classified in: Science and technology
Subject: Event

ReposiTrak Rings NYSE Closing Bell, Marking Milestone for Company and Progress Toward Traceability


ReposiTrak (NYSE: TRAK) Chairman and CEO Randy Fields, along with the company's Board of Directors and senior leadership, rang the closing bell at the New York Stock Exchange on April 30, 2024. The event marked the company's progress toward advancing food safety and traceability in the food supply chain and its uplisting from Nasdaq to the New York Stock Exchange under its new ticker (NYSE: TRAK).

"Ringing the bell at the historic New York Stock Exchange was a milestone and one that we'll never forget," said Randy Fields, chairman and CEO of ReposiTrak. "It was a moment to acknowledge the progress we've made over the last two decades in advancing food safety and traceability across the food supply chain and also, importantly, to contemplate the road ahead."

ReposiTrak, the world's largest food traceability and regulatory compliance network, leveraging its established inventory management and out-of-stock reduction SaaS platform, has evolved from the AMEX, to Nasdaq and in November 2023, to the NYSE. ReposiTrak serves a customer base of more than 30,000 retailers, wholesalers and suppliers in more than 110 countries through a robust solution suite consisting of three product families: food traceability, compliance and risk management, as well as supply chain solutions.

The company's newest offering, the ReposiTrak Traceability Network®, RTN, enables the exchange and maintenance of data between food supply chain operators, enabling customers to meet and exceed the requirements of the FDA's FSMA 204 food traceability law. Under FSMA 204, manufacturers, processors and those who pack or hold foods on the Food Traceability List (FTL) must establish and maintain Key Data Element (KDE) records for specific Critical Tracking Events (CTEs). As an FTL food changes hands or changes form, a compounding string of data must be transferred between trading partners to provide full, end-to-end traceability.

For the ceremony, Fields was joined by members of the ReposiTrak Board of Directors and senior leadership team, including but not limited to:

Board Members:

Leadership:

Watch a video of the day's events: https://repositrak.com/blog/this-week-at-the-new-york-stock-exchange-a-milestone-for-repositrak-in-advancing-food-safety-and-traceability/

About ReposiTrak

ReposiTrak (NYSE: TRAK), formerly Park City Group, provides retailers, suppliers and wholesalers with a robust solution suite consisting of three product families: food traceability, compliance and risk management and supply chain solutions. ReposiTrak's integrated, cloud-based applications are supported by an unparalleled team of experts. For more information, please visit https://repositrak.com/.


These press releases may also interest you

at 03:30
Amflow, the eMTB expert that builds e-bikes from heart to body, today marks its entry into the industry with the launch of the Amflow PL. Providing a significantly robust 850 W of peak power and weighing in at an industry leading level of ultra-light...

at 03:17
Daniels Manufacturing Corporation® (DMC®) is proud to announce the successful acquisition of MCD-Tools GmbH, a leading tool distribution and repair company based near Frankfurt, Germany. DMC's acquisition of MCD-Tools allows DMC to form DMC Europe...

at 03:05
NielsenIQ (NIQ) today announced the availability of NIQ Activate in the Microsoft Azure Marketplace, an online store providing applications and services for use on Azure. NIQ customers can now take advantage of the productive and trusted Azure cloud...

at 03:05
Owkin, the first end-to-end AI-biotech unicorn that provides best-in-class AI-driven precision drug discovery, development and diagnostics, has announced its expansion into the DACH region (Germany, Austria and Switzerland) following partnerships...

at 03:05
Manhattan Associates today announced that it has been named winner of the VIP Awards' Best Sustainability Initiative category for 2024. Selected from a competitive group of nominees, Manhattan Active® Supply Chain technology was chosen because of...

at 03:05
We are excited to share our latest development status. We are pleased to announce that the enrollment of patients in the Phase III clinical trial of DFP-14323 in combination with Afatinib (20 mg/day) versus Afatinib (40 mg/day) alone in stage...



News published on and distributed by: